WuXi AppTec acquires preclinical CRO

By Melissa Fassbender

- Last updated on GMT


Related tags Corporation Subsidiary

WuXi AppTec has acquired Shanghai-based HD Biosciences (HDB), a biology-focused preclinical contract research organization (CRO). 

HD Biosciences, which also has facilities in Beijing and the US, will become a wholly-owned subsidiary of WuXi.

According to WuXi AppTec, the acquisition will strengthen the company’s research and development capabilities from target validation to lead discovery and optimization.

HD Biosciences’ capabilities include plate-based pharmacology and screening as well as AGMTM based target validation.

In a press statement, Dr. Xuehai Tan, Chairman and CEO of HD Biosciences, said the integration of services will enable the company to meet its growing customer needs.

Related topics Preclinical Research Preclinical

Related news

Show more

Related products

show more

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us


View more